A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

NCT00462761 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Leukemia
Myelodysplastic Syndrome
AML
MDS

Interventions

DRUG: AC220

Sponsor

Daiichi Sankyo